Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chromobacterium violaceum infection

Hoi-Poh Tee¹, Alex L Francis, Soon-Hin How

¹Department of Internal Medicine, Hospital Tengku Ampuan Afzan, 25100 Kuantan, Pahang, Malaysia.

British Journal of Hospital Medicine (London, England : 2005)

|May 10, 2006

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.

Lung cancer (Amsterdam, Netherlands)·2026

Same author

Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC.

The New England journal of medicine·2025

Same author

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC.

The New England journal of medicine·2024

Same author

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Journal of gastroenterology and hepatology·2022

Same author

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.

The lancet. Gastroenterology & hepatology·2021

Same author

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.

BMC cancer·2019